A major milestone brings faster, smarter, and more flexible glucose monitoring to people living with type 1 diabetes.
Minneapolis, Minnesota, 4 December 2025 – Medtronic has officially launched its MiniMed 780G insulin delivery system integrated with Abbott’s new Instinct continuous glucose monitoring (CGM) sensors in the United States. This marks a major step forward in a partnership first announced in 2024 and represents a new era of flexibility and innovation for diabetes technology users.
The MiniMed 780G is one of Medtronic’s most advanced diabetes management systems. Its newly added compatibility with Abbott’s Instinct sensors, approved by the U.S. Food and Drug Administration in September, allows the system to serve a wider range of patients with type 1 diabetes. For the first time, people in the U.S. can use this automated insulin dosing technology with Abbott’s next-generation sensors.
Que Dallara, executive vice president and president of Medtronic’s diabetes division, emphasized that this milestone expands patient freedom and choice. She noted that the goal is simple: to make life with diabetes easier, more predictable, and less burdensome for both patients and their families.
Abbott’s Instinct sensors are the latest evolution in CGM technology. Lightweight and compact at just 0.11 x 0.83 inches, they can be worn for 15 days, offering long-lasting accuracy and comfort. The sensors automatically adjust insulin every five minutes when paired with the MiniMed 780G system, helping users maintain stable glucose levels throughout the day.
The Instinct sensors are approved for individuals with type 1 diabetes aged seven and older. Their one-hour warm-up time is the fastest among sensors compatible with the MiniMed 780G, giving users quicker access to real-time glucose insights.
With shipments already underway, U.S. patients can now begin experiencing this combined system designed to reduce daily diabetes management stress and support better long-term health outcomes.
